托珠单抗治疗类风湿关节炎的疾病活动改善不受CCP状态影响
基于CORRONA类风湿关节炎注册数据库的真实世界队列研究,评估起始托珠单抗治疗后4-8个月随访时医生和患者报告的结局及实验室指标变化。结果显示CCP阴性和阳性两组在医生报告指标、患者报告指标及急性期反应物上均有统计学显著改善,但改善幅度在CCP状态间无显著差异。
要点
- 托珠单抗治疗4-8个月后,CCP阴性和阳性RA患者疾病活动均有统计学显著改善。
- 医生报告指标、患者报告指标及急性期反应物均见改善。
- 改善幅度在CCP阴性与阳性患者间无显著差异。
核心结论
- 托珠单抗治疗使本RA队列中所有评估的患者报告和医生报告的疾病活动指标均获统计学显著改善。
- 托珠单抗的应答不因CCP状态而存在差异。
研究设计与样本
- 分析CORRONA类风湿关节炎注册数据库的真实世界队列数据。
- 纳入起始托珠单抗治疗且有起始后4-8个月随访数据及血清学状态信息的患者。
- 血清学状态由抗环瓜氨酸肽(CCP)抗体存在与否确定。
主要发现
- CCP阴性和阳性两组在托珠单抗治疗4-8个月后,医生报告的疾病活动评分和关节计数均有统计学显著改善。
- 两组患者报告的疾病活动、疼痛和疲劳均有统计学显著改善。
- 两组急性期反应物均有统计学显著改善。
- 改善幅度在CCP状态间无统计学显著差异。
临床怎么用
- 在真实世界RA患者中,无论CCP状态如何,托珠单抗均可改善疾病活动指标。
- CCP状态不应作为限制托珠单抗使用的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient-reported outcomes and laboratory parameters in a real-world cohort of patients with RA. We analyzed the data by autoantibody status to determine whether patients with seronegative RA had improved response to tocilizumab when compared to their seropositive counterparts. METHODS: Data from the CORRONA RA registry were analyzed. Patients were included if they were started on TCZ and had data from a follow-up visit 4-8 months after initiation, as well as having information on serologic status. Serologic status was determined by presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow-up visit were evaluated. RESULTS: Both CCP-negative and -positive groups had statistically significant improvement in physician-reported measurements (physician rating of disease activity and joint counts), patient-reported measures (disease activity, pain, and fatigue), and acute phase reactants after 4-8 months of treatment with tocilizumab. The magnitude of improvement, however, did not differ significantly by CCP status. CONCLUSION: Tocilizumab led to statistically significant improvement in all patient- and physician-reported measures of disease activity evaluated in this cohort of patient with RA. The response to tocilizumab did not differ by CCP status.
引用
- Cappelli LC, Palmer JL, Kremer J, et al. Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis. Semin Arthritis Rheum. 2017. PMID: 28477897. doi:10.1016/j.semarthrit.2017.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。